Goa-based Molbio Gets Testing Nod for Covid-19 Kit
Mumbai: Goa-based Molbio said that it has received a testing licence from the Drug Controller General of India for its Covid-19 kits, a move that takes it one step closer to the launching them in the Indian market.
Molbio said that its point of care instrument can give out results in 35 minutes, which would make it the only Indian firm to provide quicker results.
The regulator’s approval means that the National Institute of Infectious Studies (Pune), which is the central lab for all the Covid-19 tests in the country, will validate whether Molbio's device actually works.
Molbio received over ₹100 crore funding last week from private equity firm Motilal Oswal. It is already doing testing for TB detection in India.
“Our point of care system ensures that it is not restricted to only central labs. We can go to remote parts or even homes and get the tests done,” said Sriram Natarajan, CEO of Molbio.
He said that there are three versions of its testing kits. The first one can give out 12 tests, the second version 24 and third the advanced can do 48 tests a day and each test results will be out in 30 minutes.
Earlier this week Swiss diagnostics firm Roche also said that the company had received approval for its SARS-Covid-19 diagnostic that can test thousands of samples in 24 hours. Though Roche’s tests works on large equipment that is not available in the country, the company said it will look at ways of addressing this. “We have the potential to offer three types of test kits that can be used to screen and further diagnose Covid-19 infections on our existing systems that run other infectious disease panels,” Shravan Subramaniam, MD Roche Diagnostics had told ET earlier.